Join the Tacrolimus group to help and get support from people like you.
Tacrolimus News
Related terms: Tacrolimus Topical
Tacrolimus Microemulsion Has Good Efficacy, Safety for Scalp Psoriasis
TUESDAY, March 5, 2024 – For scalp psoriasis, 0.1 percent tacrolimus microemulsion has good efficacy and safety, according to a study published online Feb. 12 in Dermatology and Therapy. Andreas...
FDA Medwatch Alert: FDA is Changing the Therapeutic Equivalence Rating for Accord Healthcare Inc.’s Generics of Prograf (tacrolimus) Oral Capsules
September 18, 2023 – Based on new data, the U.S. Food and Drug Administration is changing the therapeutic equivalence rating for tacrolimus oral capsule products manufactured by Accord Healthcare...
U.S. Food and Drug Administration Expands Indication for Prograf for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients
NORTHBROOK, Ill., July 20, 2021 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves New Indication for Envarsus XR (tacrolimus extended-release tablets)
COPENHAGEN, Denmark, Dec. 19, 2018 /PRNewswire/ – Veloxis Pharmaceuticals announced today that the U.S. Food & Drug Administration (FDA) approved a new indication for Envarsus XR (tacrolimus...
FDA Approves Envarsus XR (tacrolimus) for Prevention of Organ Rejection in Kidney Transplant Patients
Hørsholm, Denmark, July 10, 2015 – Veloxis Pharmaceuticals A/S (OMX: VELO) today announced U.S. Food and Drug Administration (FDA) approval of Envarsus XR (tacrolimus extended-release tablets) for ...
Astellas Announces FDA Approval of Astagraf XL (tacrolimus extended-release capsules) for the Prophylaxis of Organ Rejection
NORTHBROOK, Ill., July 19, 2013 /PRNewswire/ – Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug...
Ask a question
To post your own question to this support group, sign in or create an account.